Cytological criteria of differentiation of phyllodes tumor of the breast and fibroadenoma
https://doi.org/10.17650/1994-4098-2019-15-1-19-28
Abstract
The article is devoted to the determination of the cytological criteria of differentiation of fibroadenoma and phyllodes tumor. By means of multivariate analysis the 11 most informative cellular signs of fibroadenoma, juvenile fibroadenoma and benign phyllodes tumors were identified. According to the discriminant analysis, only 37.97 % of patients with benign phyllodes tumors are classified correctly, that indicates the difficulties of differentiation of these tumors. Some cellular signs of fibroadenoma, borderline and malignant phyllodes tumor allow to diagnose these forms of tumors.
About the Author
О. G. Grigoruk
Altai Regional Oncology Dispensary;
Altai State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
110k Zmeinogorskiy tract, Barnaul 656045,
40 Lenin Prospect, Barnaul 656038
References
1. Shaaban M., Barthelmes L. Benign phyllodes tumours of the breast: (Over) treatment of margins – a literature review. Eur J Surg Oncol 2017;43(7):1186–90. DOI: 10.1016/j.ejso.2016.10.019.
2. Tse G.M., Niu Y., Shi H.J. Phyllodes tumor of the breast: an update. Breast Cancer 2010;17:29–34. DOI: 10.1007/s12282009-0114-z.
3. Jacklin R.K., Ridgway P.F., Ziprin P. et al. Optimising preoperative diagnosis in phyllodes tumour of the breast. J Clin Pathol 2006;59:454–9. DOI: 10.1136/jcp.2005.025866.
4. Abe M., Miyata S., Nishimura S. et al. Malignant transformation of breast fibroadenoma to malignant phyllodes tumor: long-term outcome of 36 malignant phyllodes tumors. Breast Cancer 2011;18:268–72. DOI: 10.1007/s12282-009-0185-х.
5. Foucar C.E., Hardy A., Siziopikou K.P. et al. A mother and daughter with phyllodes tumors of the breast. Clin Breast Cancer 2012;12:373–7. DOI: 10.1016/j.clbc.2012.07.011.
6. Lim W.K., Ong C.K., Tan J. et al. Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. Nat Genet 2014;46:877–80. DOI: 10.1038/ng.3037.
7. Cani A.K., Hovelson D.H., McDaniel A.S. et al. Next-gen sequencing exposes frequent MED12 mutations and actionable therapeutic targets in phyllodes tumors. Mol Cancer Res 2015;13:613–9. DOI: 10.1158/1541-7786.MCR-14-0578.
8. Yoshida M., Sekine S., Ogawa R. et al. Frequent MED12 mutations in phyllodes tumours of the breast. Br J Cancer 2015;112:1703–8. DOI: 10.1038/bjc.2015.116.
9. Pfarr N., Kriegsmann M., Sinn P. et al. Distribution of MED12 mutations in fibroadenomas and phyllodes tumors of the breast – implications for tumor biology and pathological diagnosis. Genes Chromosom Cancer 2015;54:444–52. DOI: 10.1002/gcc.22256.
10. Nagasawa S., Maeda I., Fukuda T. et al. MED12 exon 2 mutations in phyllodes tumors of the breast. Cancer Med 2015;7:1117–21. DOI: 10.1002/cam4.462.
11. Ng C.C.Y., Tan J., Ong C.K. et al. MED12 is frequent mutated in breast phyllodes tumours: a study of 112 cases. J Clin Pathol 2015;68:685–91. DOI: 10.1136/jclinpath2015-202896.
Review
For citations:
Grigoruk О.G. Cytological criteria of differentiation of phyllodes tumor of the breast and fibroadenoma. Tumors of female reproductive system. 2019;15(1):19-28. (In Russ.) https://doi.org/10.17650/1994-4098-2019-15-1-19-28
Views:
1400
Email this article 